Ituxredi

Ituxredi is a medicine used to treat the following blood cancers and inflammatory conditions: * follicular lymphoma and diffuse large B cell non\-Hodgkin’s lymphoma (two types of non\-Hodgkin’s lymphoma, a blood cancer); * chronic lymphocytic leukaemia (CLL, another blood cancer affecting white blood cells); * severe rheumatoid arthritis (an inflammatory condition of the joints); * two inflammatory conditions of blood vessels known as granulomatosis with polyangiitis (GPA or Wegener’s granulomatosis) and microscopic polyangiitis (MPA); * moderate to severe pemphigus vulgaris, an autoimmune disease characterised by widespread blistering and erosion of the skin and mucous membranes (the linings of internal organs). ‘Autoimmune’ means that the disease is caused by the immune system (the body’s natural defences) attacking the body’s own cells. Depending on the condition it is used to treat, Ituxredi may be given on its own, or with chemotherapy, methotrexate or a corticosteroid. Ituxredi is a ‘biosimilar medicine’. This means that Ituxredi is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Ituxredi is MabThera. Ituxredi contains the active substance rituximab.